Xintela AB
1XT
Company Profile
Business description
Xintela AB is a biomedical company that develops stem cell-based treatments with a focus on osteoarthritis and hard-to-heal leg wounds as well as, through the wholly-owned subsidiary Targinta, targeted antibody-based treatments for aggressive cancers such as triple-negative breast cancer and the brain tumor glioblastoma.
Contact
Medicon Village
Lund22381
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
stocks
Lower moat ratings on four ASX shares due to AI
We believe AI weakens the competitive advantage of these companies.
stocks
What Q4 US earnings did and didn’t tell us about AI and the outlook for tech shares
Tech saw solid earnings, but there are more questions around which companies will benefit from AI, and which will be hurt.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,733.70 | 106.80 | -1.21% |
| CAC 40 | 7,993.49 | 52.31 | -0.65% |
| DAX 40 | 23,591.03 | 224.72 | -0.94% |
| Dow JONES (US) | 47,501.55 | 453.19 | -0.95% |
| FTSE 100 | 10,284.75 | 129.19 | -1.24% |
| HKSE | 25,135.35 | 621.94 | -2.41% |
| NASDAQ | 22,387.68 | 361.31 | -1.59% |
| Nikkei 225 | 51,740.46 | 3,880.38 | -6.98% |
| NZX 50 Index | 13,087.37 | 530.52 | -3.90% |
| S&P 500 | 6,740.02 | 90.69 | -1.33% |
| S&P/ASX 200 | 8,509.80 | 92.50 | -1.08% |
| SSE Composite Index | 4,081.89 | 42.30 | -1.03% |